The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Novel approaches in Richter’s transformation: CAR-T and bispecifics
Geoffrey Shouse, DO, PhD, City of Hope, Duarte, CA, discusses the unmet needs in Richter’s transformation (RT), commenting on the possibility of using CAR T-cell therapy and bispecific antibodies in these patients. Dr Shouse highlights that novel therapeutic approaches and combinations will be needed to overcome the inhibitory immune microenvironment observed in RT. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
